1,3,5-Triazine-based analogues of purine: From isosteres to privileged scaffolds in medicinal chemistry

被引:75
作者
Lim, Felicia Phei Lin [1 ]
Dolzhenko, Anton V. [1 ,2 ]
机构
[1] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm, Perth, WA 6845, Australia
[2] Monash Univ Malaysia, Sch Pharm, Bandar Sunway 47500, Selangor Darul, Malaysia
关键词
Isostere; Purine; Triazine; Enzyme inhibitor; Anticancer; Antiviral; CORTICOTROPIN-RELEASING-FACTOR; XANTHINE-OXIDASE INHIBITOR; A(2A) RECEPTOR ANTAGONISTS; ANTI-THYMIDINE PHOSPHORYLASE; IN-VITRO; STEREOSELECTIVE PHARMACOKINETICS; PHARMACOLOGICAL-ACTIVITY; PIPERAZINE DERIVATIVES; BIOLOGICAL EVALUATION; ASYMMETRIC-SYNTHESIS;
D O I
10.1016/j.ejmech.2014.07.112
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Purines can be considered as the most ubiquitous and functional N-heterocyclic compounds in nature. Structural modifications of natural purines, particularly using isosteric ring systems, have been in the focus of many drug discovery programs. Fusion of 1,3,5-triazine ring with pyrrole, pyrazole, imidazole, 1,2,3-triazole or 1,2,4-triazole results in seven bicyclic heterocyclic systems isosteric to purine. Application of the isosterism concept for the development of new compounds with therapeutic potential in areas involving purinergic regulation or purine metabolism led to significant advances in medicinal chemistry of the azolo[1,3,5]triazines. These 1,3,5-triazine-based purine-like scaffolds significantly increase level of molecular diversity and allow covering chemical space in the important areas of medicinal chemistry. Some of these azolo[1,3,5]triazine systems have become privileged scaffolds in the development of inhibitors of various kinases, phosphodiesterase, xanthine oxidase, and thymidine phosphorylase, antagonists of adenosine and corticotropin-releasing hormone receptors, anticancer and antiviral agents. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:371 / 390
页数:20
相关论文
共 201 条
[51]  
Eickhoff J., 2013, EP Patent, Patent No. 2634189
[52]  
Eickhoff J., 2013, WO Patent, Patent No. 2013128029
[53]  
Eickhoff J., 2013, Patent No. [2013128028A1, 2013128028]
[54]   Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A2A Adenosine Receptor Antagonists with Improved Water Solubility [J].
Federico, Stephanie ;
Paoletta, Silvia ;
Cheong, Siew Lee ;
Pastorin, Giorgia ;
Cacciari, Barbara ;
Stragliotto, Stefano ;
Klotz, Karl Norbert ;
Siegel, Jeffrey ;
Gao, Zhan-Guo ;
Jacobson, Kenneth A. ;
Moro, Stefano ;
Spalluto, Giampiero .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (03) :877-889
[55]  
Feng J., 2006, US Patent, Patent No. 20060135767
[56]   Current Research on Opioid Receptor Function [J].
Feng, Yuan ;
He, Xiaozhou ;
Yang, Yilin ;
Chao, Dongman ;
Lazarus, Lawrence H. ;
Xia, Ying .
CURRENT DRUG TARGETS, 2012, 13 (02) :230-246
[57]  
Francis SH, 2011, HANDB EXP PHARMACOL, V204, P47, DOI [10.1007/978-3-642-17969-3_2, 10.1007/978-3-642-13443-2_4]
[58]   International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors-An Update [J].
Fredholm, Bertil B. ;
IJzerman, Adriaan P. ;
Jacobson, Kenneth A. ;
Linden, Joel ;
Mueller, Christa E. .
PHARMACOLOGICAL REVIEWS, 2011, 63 (01) :1-34
[59]  
Fujii S., 1988, EP Patent, Patent No. 269859
[60]  
Gallorini M, 2012, BIODRUGS, V26, P377, DOI 10.2165/11634060-000000000-00000